Read by QxMD icon Read

Psa evaluation

shared collection
27 papers 0 to 25 followers Questioning Medicine podcast and MedPage Today article. @medquestioning and @andrewBuelt. Listen/read/comment!
By Joe Weatherly FM/Hospitalist-CoFounder of QuestioningMedicine and PCRAP contributor.
Eveline A M Heijnsdijk, Elisabeth M Wever, Anssi Auvinen, Jonas Hugosson, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Arnauld Villers, Alvaro Páez, Sue M Moss, Marco Zappa, Teuvo L J Tammela, Tuukka Mäkinen, Sigrid Carlsson, Ida J Korfage, Marie-Louise Essink-Bot, Suzie J Otto, Gerrit Draisma, Chris H Bangma, Monique J Roobol, Fritz H Schröder, Harry J de Koning
BACKGROUND: After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of life resulting from overdiagnosis and treatment counterbalance this benefit is uncertain. METHODS: On the basis of ERSPC follow-up data, we used Microsimulation Screening Analysis (MISCAN) to predict the number of prostate cancers, treatments, deaths, and quality-adjusted life-years (QALYs) gained after the introduction of PSA screening...
August 16, 2012: New England Journal of Medicine
David D Ørsted, Stig E Bojesen, Pia R Kamstrup, Børge G Nordestgaard
BACKGROUND: It remains unclear whether adding long-term prostate-specific antigen velocity (PSAV) to baseline PSA values improves classification of prostate cancer (PCa) risk and mortality in the general population. OBJECTIVE: To determine whether long-term PSAV improves classification of PCa risk and mortality in the general population. DESIGN, SETTING, AND PARTICIPANTS: We studied 503 men aged 30-80 yr, with and without PCa, who had repeated PSA measurements over 20 yr and up to 28 yr before PCa diagnosis...
September 2013: European Urology
Ian E Haines, George L Gabor Miklos
Major clinical trials using prostate-specific antigen (PSA) as the screening test to detect localized early-stage prostate cancer and to attempt to change its natural history with early intervention have yielded conflicting interpretations. The US Prostate, Lung, Colorectal, and Ovarian (US PLCO) cancer screening trial concluded that PSA-based screening conferred no meaningful survival benefit, whereas the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the GOTEBORG clinical trial (GOTEBORG) trials claimed statistically significant life-saving benefits...
October 16, 2013: Journal of the National Cancer Institute
Leonard P Bokhorst, Chris H Bangma, Geert J L H van Leenders, Jan J Lous, Sue M Moss, Fritz H Schröder, Monique J Roobol
BACKGROUND: Large randomized screening trials provide an estimation of the effect of screening at a population-based level. The effect of screening for individuals, however, is diluted by nonattendance and contamination in the trial arms. OBJECTIVE: To determine the prostate cancer (PCa) mortality reduction from screening after adjustment for nonattendance and contamination. DESIGN, SETTING, AND PARTICIPANTS: A total of 34,833 men in the core age group, 55-69 yr, were randomized to a screening or control arm in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)...
February 2014: European Urology
Fritz Schröder, Chris Bangma, Javier C Angulo, Antonio Alcaraz, Marc Colombel, Tom McNicholas, Teuvo L Tammela, Indrani Nandy, Ramiro Castro
BACKGROUND: Rising prostate-specific antigen (PSA) levels after radical therapy are indicative of recurrent or residual prostate cancer (PCa). This biochemical recurrence typically predates clinically detectable metastatic disease by several years. Management of patients with biochemical recurrence is controversial. OBJECTIVE: To assess the effect of dutasteride on progression of PCa in patients with biochemical failure after radical therapy. DESIGN, SETTING, AND PARTICIPANTS: Randomised, double-blind, placebo-controlled trial in 294 men from 64 centres across 9 European countries...
May 2013: European Urology
Tobias Nordström, Markus Aly, Mark S Clements, Caroline E Weibull, Jan Adolfsson, Henrik Grönberg
BACKGROUND: Prostate-specific antigen (PSA) testing has increased in several countries. There is incomplete knowledge of PSA testing patterns. OBJECTIVE: Determine the prevalence of PSA testing and explore patterns of PSA retesting in Stockholm County, Sweden. DESIGN, SETTING, AND PARTICIPANTS: A population-based study was performed. Through registry linkages, we collected population information, data on PSA tests, pathology reports, and clinical information...
March 2013: European Urology
David D Orsted, Børge G Nordestgaard, Gorm B Jensen, Peter Schnohr, Stig E Bojesen
BACKGROUND: It is largely unknown whether prostate-specific antigen (PSA) level at first date of testing predicts long-term risk of prostate cancer (PCa) incidence and mortality in the general population. OBJECTIVE: Determine whether baseline PSA levels predict long-term risk of PCa incidence and mortality. DESIGN, SETTING, AND PARTICIPANTS: We examined 4383 men aged 20-94 yr from the Danish general population in the prospective Copenhagen City Heart Study...
May 2012: European Urology
Fred Saad, Scott Segal, James Eastham
BACKGROUND: Zoledronic acid (ZOL) is a standard therapy for the prevention of skeletal-related events (SREs) in patients with castration-resistant prostate cancer (CRPC). Although prostate-specific antigen (PSA) is an established marker for monitoring prostate cancer patients, correlations between PSA and disease outcomes during ZOL therapy are unclear. OBJECTIVE: To evaluate the relationships among PSA kinetics, bone-directed therapy with ZOL, and clinical outcomes in men with bone metastases from CRPC using a ZOL phase 3 trial database...
January 2014: European Urology
Christopher J Keto, William J Aronson, Martha K Terris, Joseph C Presti, Christopher J Kane, Christopher L Amling, Stephen J Freedland
BACKGROUND: A prostate-specific antigen (PSA) level <0.2 ng/ml 8 mo after starting on androgen-deprivation therapy (ADT) is correlated with better outcomes. However, not all men reach a nadir PSA level within 8 mo. Whether the lowest PSA on ADT-specifically, <0.2 ng/ml-can be used for risk stratification is untested. OBJECTIVE: We examined the predictive value of small but detectable PSA nadir values on prostate cancer (PCa)-specific outcomes in men treated with early ADT after radical prostatectomy (RP)...
March 2014: European Urology
Stacy Loeb, H Ballentine Carter, William J Catalona, Judd W Moul, Fritz H Schroder
CONTEXT: Prostate cancer screening is highly controversial, including the age to begin prostate-specific antigen (PSA) testing. Several studies have evaluated the usefulness of baseline PSA measurements at a young age. OBJECTIVE: Review the literature on baseline PSA testing at a young age (≤60 yr) for the prediction of prostate cancer risk and prognosis. EVIDENCE ACQUISITION: PubMed was searched for English-language publications on baseline PSA and prostate cancer for the period ending April 2011...
January 2012: European Urology
Kerry N L Avery, Chris Metcalfe, Kavita Vedhara, J Athene Lane, Michael Davis, David E Neal, Freddie C Hamdy, Jenny L Donovan, Jane M Blazeby
BACKGROUND: Little is known about factors influencing men's decisions to undergo screening and diagnostic tests for prostate cancer (PCa). OBJECTIVE: Identify predictors of attendance for prostate-specific antigen (PSA) testing and prostate biopsy. DESIGN, SETTING, AND PARTICIPANTS: Literature searches and interviews with men undergoing PSA testing and prostate biopsy formed the basis of a self-report questionnaire designed to identify predictors of health behaviour, which was completed by men eligible for PSA invitation and prostate biopsy...
October 2012: European Urology
Siva K Mulpuru, Karthik Gujja, Vinay M Pai, Christina Y Y Chen, Robert L Levey
Sarcoidosis and prostate cancer are 2 separate conditions that are more prevalent among the African American population. However, sarcoidosis of the prostate is a very rare clinical entity. Its association with prostate cancer is described in clinical case series. The use of PSA (prostate specific antigen) test for screening prostate cancer may be associated with false-positive results in this patient population. We report a patient who had an elevated PSA but had a biopsy proven to be sarcoidosis of the prostate gland...
March 2008: American Journal of the Medical Sciences
Susan Halabi, Andrew J Armstrong, Oliver Sartor, Johann de Bono, Ellen Kaplan, Chen-Yen Lin, Nicole C Solomon, Eric J Small
PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy. PATIENTS AND METHODS: Data from a phase III trial of patients with mCRPC randomly assigned to cabazitaxel plus prednisone (C + P) or mitoxantrone plus prednisone were used...
November 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Ian M Thompson, Robin J Leach, Donna P Ankerst
No abstract text is available yet for this article.
September 10, 2014: JAMA: the Journal of the American Medical Association
Peter Hjertholm, Morten Fenger-Grøn, Mogens Vestergaard, Morten B Christensen, Michael Borre, Henrik Møller, Peter Vedsted
Knowledge is sparse about the consequences of variation in prostate-specific antigen (PSA) testing rates in general practice. This study investigated associations between PSA testing and prostate cancer- related outcomes in Danish general practice, where screening for prostate cancer is not recommended. National registers were used to divide general practices into four groups based on their adjusted PSA test rate 2004-2009. We analysed associations between PSA test rate and prostate cancer-related outcomes using Poisson regression adjusted for potential confounders...
January 15, 2015: International Journal of Cancer. Journal International du Cancer
Linda B Squiers, Carla M Bann, Suzanne E Dolina, Janice Tzeng, Lauren McCormack, Douglas Kamerow
BACKGROUND: The U.S. Preventive Services Task Force (USPSTF) released a draft recommendation advising against prostate-specific antigen (PSA) testing in October 2011, a major shift from previous years of recommending neither for or against PSA testing due to insufficient evidence. PURPOSE: The purpose of this study was to assess men's awareness of the new recommendation, and their responses to it. METHODS: This study comprised a web survey of men aged 40-74 years that was conducted through GfK Custom Research, LLC's Knowledge Panel® from November 22 to December 2, 2011...
August 2013: American Journal of Preventive Medicine
Paul K J Han, Sarah Kobrin, Nancy Breen, Djenaba A Joseph, Jun Li, Dominick L Frosch, Carrie N Klabunde
PURPOSE: Recent clinical practice guidelines on prostate cancer screening using the prostate-specific antigen (PSA) test (PSA screening) have recommended that clinicians practice shared decision making-a process involving clinician-patient discussion of the pros, cons, and uncertainties of screening. We undertook a study to determine the prevalence of shared decision making in both PSA screening and nonscreening, as well as patient characteristics associated with shared decision making...
July 2013: Annals of Family Medicine
Jeannette M Schenk, Rachel Hunter-Merrill, Yingye Zheng, Ruth Etzioni, Roman Gulati, Catherine Tangen, Ian M Thompson, Alan R Kristal
Although surrogate measures of benign prostatic hyperplasia (BPH) are often used in epidemiologic studies, their performance characteristics are unknown. Using data from the Prostate Cancer Prevention Trial (n = 5,986), we evaluated prostate-specific antigen (PSA), International Prostate Symptom Score (IPSS), and their rates of change as predictors of incident BPH. BPH (n = 842 cases) was defined as medical or surgical treatment or at least 2 IPSS of 15 or higher. Proportional hazards models were used to measure the associations of baseline PSA, IPSS, and their velocities over 2 years with BPH risk, and time-dependent receiver-operating characteristic curves were used to measure their discriminatory performance...
September 1, 2013: American Journal of Epidemiology
Monique J Roobol, Ries Kranse, Chris H Bangma, Arno G J L H van Leenders, Bert G Blijenberg, Ron H N van Schaik, Wim J Kirkels, Suzie J Otto, Theo H van der Kwast, Harry J de Koning, Fritz H Schröder
BACKGROUND: Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up. OBJECTIVE: To assess data on PCa-specific mortality in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial. DESIGN, SETTING, AND PARTICIPANTS: A randomized controlled trial with randomization after signed, written informed consent (efficacy trial)...
October 2013: European Urology
Roman Gulati, John L Gore, Ruth Etzioni
BACKGROUND: The U.S. Preventive Services Task Force recently concluded that the harms of existing prostate-specific antigen (PSA) screening strategies outweigh the benefits. OBJECTIVE: To evaluate comparative effectiveness of alternative PSA screening strategies. DESIGN: Microsimulation model of prostate cancer incidence and mortality quantifying harms and lives saved for alternative PSA screening strategies. DATA SOURCES: National and trial data on PSA growth, screening and biopsy patterns, incidence, treatment distributions, treatment efficacy, and mortality...
February 5, 2013: Annals of Internal Medicine
2014-11-12 00:08:05
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"